Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 15/20 | 0.44 |
| ▸ | CA2 | P00918 | 15/20 | 0.44 |
| ▸ | CA4 | P22748 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Versetamide SCHEMBL23202642 | 0.98 | TDP1 (0.48) | TDP1BLMPMP22KDM4ELMNA | |
| Versetamide SCHEMBL15844631 | 0.98 | TDP1 (0.48) | TDP1BLMPMP22KDM4ELMNA | |
| Versetamide SCHEMBL2109367 | 0.97 | TDP1 (0.50) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL8103783 | 0.97 | TDP1 (0.50) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL8089255 | 0.95 | TDP1 (0.48) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL5547592 | 0.88 | BLM (0.50) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL15397125 | 0.87 | TDP1 (0.40) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL8089127 | 0.81 | BLM (0.47) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL24024217 | 0.81 | BLM (0.47) | TDP1BLMPMP22KDM4ELMNA | |
| Versetamide SCHEMBL237265 | 0.81 | KDM4E (0.43) | TDP1KDM4EALOX15TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725558-A2 | IMMUNOABLATIVE THERAPIES | AVM Biotechnology, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3860612-B1 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY LLC (US) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025245288-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025245292-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025245294-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4637799-A1 | MEDICAL PRODUCTS CONTAINING AN AQUEOUS FORMULATION OF A PEPTIDE | Lytix Biopharma AS (NO) | 2025-10-29 | — | — | EP | disclosed |
| US-20250255801-A1 | Novel Parenteral Composition Comprising Linagliptin or its Salts | ZENVISION PHARMA LLP (IN) | 2025-08-14 | — | — | US | disclosed |
| WO-2025123059-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR TREATING SUBSTANCE USE DISORDERS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025123055-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20200108078-A1 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY, LLC | 2020-04-09 | — | — | US | disclosed |
| WO-2020072713-A1 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY, LLC (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-3632446-A1 | IMMUNOABLATIVE THERAPIES | AVM Biotechnology, LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2019180199-A1 | STABLE AQUEOUS COMPOSITION OF PHOSPHOCREATINE | ALFASIGMA S.P.A. (IT) | 2019-09-26 | — | — | WO | disclosed |
| EP-3488851-A1 | IMMUNOABLATIVE THERAPIES | AVM Biotechnology, LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-10159661-B2 | Penicillin retard composition for intramuscular injection | SANDOZ AG (CH) | 2018-12-25 | — | — | US | disclosed |
| US-20180036291-A1 | Penicillin Retard Composition For Intramuscular Injection | SANDOZ AG (CH) | 2018-02-08 | — | — | US | disclosed |
| EP-3261615-A1 | PENICILLIN RETARD COMPOSITION FOR INTRAMUSCULAR INJECTION | Sandoz AG (CH) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135075-A1 | PENICILLIN RETARD COMPOSITION FOR INTRAMUSCULAR INJECTION | SANDOZ AG (CH) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016097240-A1 | PROCESS FOR PRODUCING STERILE SOLUTIONS CONTAINING A CELLULOSE ETHER DERIVATIVE | SANDOZ AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10159661-B2 | Penicillin retard composition for intramuscular injection | GMPS, MMP1, ITPA | TDP1 3382/4885BLM 2632/4885PMP22 1077/4885 |
| US-20180036291-A1 | Penicillin Retard Composition For Intramuscular Injection | GMPS, MMP1, ITPA | TDP1 3382/4885BLM 2632/4885PMP22 1077/4885 |
| US-20250255801-A1 | Novel Parenteral Composition Comprising Linagliptin or its Salts | SLC5A2, DPP4, SLC5A1 | TDP1 3625/4885BLM 3311/4885PMP22 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.